RxDoctor Payments Data

William Cenac, MD

Sports Medicine · New Iberia, LANPI 1629175633

Payments from drug & device makers

What this record shows

Stryker accounts for 74.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $1,904 and has fallen 85.9% since, to $269 in 2025. That places this record below the midpoint for sports medicine clinicians in LA, where the typical reported total is $3,045.

$2,743in general payments, 2019–2025

Across 68 payments — averaging $40.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Pacira Pharmaceuticals Incorporated$127
  • Johnson & Johnson$89
  • Bioventus LLC$80
  • Kowa Pharmaceuticals America, Inc.$73
  • Pacira Therapeutics, Inc.$66
  • plus $269 from 10 others

What the payments were for

  • Travel & lodging$1,22245%
  • Food & beverage$1,52155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,743 in reported general payments places this provider in the 45th percentile of 82 sports medicine providers in Louisiana.

See all sports medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$174,650
Medicare patients
327
Services billed
8,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolmetin Sodium51$123,865
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,810$31,867
Orphenadrine-Aspirin-CaffeineOrphenadrine/Aspirin/Caffeine39$30,204
EliquisApixaban23$12,644
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen444$11,622
Tizanidine Hcl429$2,345
Meloxicam834$2,045
Celecoxib143$1,953
Tramadol Hcl183$1,645
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol14$1,638
Gabapentin147$1,415
Acetaminophen-CodeineAcetaminophen With Codeine40$1,168
Fentanyl12$1,129
Cyclobenzaprine Hcl94$821
Pregabalin33$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$12,64423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 82 sports medicine providers in Louisiana.

Other sports medicine in New Iberia

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →